Humedix, a Kosdaq-listed healthcare firm, said Monday that its board of directors has recently decided to pay cash dividends.

The final cash dividend per share will be 275 won ($0.2), representing 10.39 million shares. The company said the total amount of cash dividend for the year is 2.85 billion won, and the dividend will be finalized at the annual general shareholders meeting in March.

The total dividend per share, including the 2023 interim (semi-annual) dividend of 250 won per share, will be 525 won per share, a 5 percent increase from the previous year.

Humedix announced a mid- and long-term dividend as part of its shareholder-friendly policy last year. From 2023 to 2025, the company plans to increase the dividend per share by up to 30 percent of the previous fiscal year's dividend. The dividend will be in the form of cash dividends, and interim dividends (half-yearly) and final dividends (year-end) will be implemented, considering future business prospects and investment needs.

"We decided to increase the dividend to pursue the interests of shareholders and practice shareholder-friendly management," a Humedix official said. "We will continue to lead the company's long-term growth through continuous endeavors and make efforts to return to shareholders."

Humedix posted sales of 152.3 billion won, operating income of 37.3 billion won, and net profit of 26.5 billion won based on individual financial statements last year. These represent year-on-year growth of 24 percent, 43 percent, and 25 percent.